Alopecia Market expected to rise | Companies – Stiefel, GlaxoSmithKline, Eli Lilly and Company, Incyte Corporation, Energenesis Biomedical Co., expected to drive market

Alopecia Market expected to rise | Companies - Stiefel, GlaxoSmithKline, Eli Lilly and Company, Incyte Corporation, Energenesis Biomedical Co., expected to drive market
Alopecia Market
DelveInsight's "Alopecia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Alopecia, historical and forecasted epidemiology as well as the Alopecia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Alopecia market growth is driven by factors like increase in the prevalence of Alopecia, investments in research and development, entry of emerging therapies during the study period 2019-2032.

The Alopecia market report also offers comprehensive insights into the Alopecia market size, share, Alopecia epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Alopecia market size growth forward. 

Some of the key highlights from the Alopecia Market Insights Report:

  • Several key pharmaceutical companies, including Stiefel, GlaxoSmithKline, Eli Lilly and Company, Incyte Corporation, Energenesis Biomedical Co., Ltd., and others, are developing novel products to improve the Alopecia treatment outlook. 
  • The total Alopecia market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major markets.
  • As per DelveInsight analysis, the Alopecia market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Alopecia Market Landscape

Alopecia Overview 

Alopecia refers to temporary or permanent hair loss from the scalp or entire body as a result of genes, changes in hormones, medical conditions or aging, generally affecting men. Signs of Alopecia may include: gradual thinning of hair on top of head, circular or patchy bald spots on scalp, beard or eyebrows, sudden hair fall, full body hair loss and patches of stalling that spread over the scalp.

Different types of alopecia are as follows:

  • Alopecia areata
  • Androgenic alopecia
  • Telogen effluvium
  • Anagen effluvium
  • Traumatic alopecia
  • Tinea capitis
  • Alopecia mucinosa
  • Alopecia neoplastica

The treatment for alopecia depends on the cause behind the condition. Sometimes the hair loss may get better on its own and no treatment is needed. However in case of severe hair loss, medicines and hair transplant surgery are the available options.

Do you know the treatment paradigms for different countries? Download our Alopecia Market Sample Report

Recent Breakthroughs in the Alopecia Market:

FDA Approves Drug Hair Loss Treatment for Alopecia: The FDA has now approved a new drug to treat hair loss caused by alopecia. On June 23, the FDA announced approval for ritlecitinib, sold under the brand name Litfulo, a drug used to treat severe alopecia areata. The medicine has been approved for people 12 years and up. Alopecia areata is an autoimmune disease that results in hair loss. This disease affects as many as 6.7 million people in the U.S.

Alopecia Epidemiology Segmentation 

DelveInsight’s Alopecia market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Alopecia historical patient pools and forecasted Alopecia patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Alopecia Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

  • Alopecia Prevalence 
  • Age-Specific Alopecia Prevalence 
  • Gender-Specific Alopecia Prevalence 
  • Diagnosed and Treatable Cases of Alopecia

Visit for more @ Alopecia Epidemiological Insights

Alopecia Treatment Market 

The Alopecia market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Alopecia market trends by analyzing the impact of current Alopecia therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Alopecia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alopecia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alopecia market in 7MM is expected to witness a major change in the study period 2019-2032.

Alopecia Emerging Drugs

KX-826: Kintor Pharma

KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (AGA) and acne vulgaris. For the AGA indication, on 8 September 2021, Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile. On 11 July 2021, Kintor Pharma announced that the Food and Drug Administration of the United States greenlighted KX-826’s phase II clinical trial for AGA to be conducted in the United States. On 31 December 2021, Kintor Pharma announced the first patient dosing in its phase III clinical trial of KX-826 in China for the treatment of male AGA patients, with 26 sites participating in this trial. On 12 November 2021, Kintor Pharma announced the first patient dosing in its phase II clinical trial of KX-826 in China for the treatment of female AGA patients. For the acne vulgaris indication, on 24 January 2022, Kintor Pharma announced the first patient dosing in its phase II clinical trial of KX-826 in China for the treatment of acne vulgaris.

Baricitinib: Reata Pharmaceuticals

Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signalling molecules and proinflammatory mediators.

Alopecia Key Companies

  • Kintor Pharma
  • Eli Lilly and Company
  • Addpharma
  • TechnoDerma Medicines
  • Energenesis Biomedical
  • Pfizer
  • Biosplice Therapeutics, Inc.
  • Concert Pharmaceuticals
  • Suzhou Zelgen Biopharmaceuticals
  • Legacy Healthcare SA
  • Eurofarma Laboratorios S.A.
  • 3SBio
  • Arena Pharmaceuticals
  • AnaptysBio, Inc.
  • Reistone Biopharma Company Limited
  • Biosplice Therapeutics, Inc.
  • LEO Pharma
  • Intrepid Therapeutics
  • Aclaris Therapeutics, Inc.
  • Bioniz Therapeutics
  • Dong-A ST
  • Hope Medicine (Nanjing) Co., Ltd
  • Inventage Lab., Inc.
  • Chong Kun Dang
  • Maxinovel Pharmaceuticals
  • Cutia Therapeutics(Wuxi)Co.,Ltd
  • Applied Biology, Inc.
  • AndroScience Corporation
  • HCW Biologics
  • Omega Therapeutics
  • Arcutis Inc
  • OnQuality Pharmaceuticals
  • APstem Therapeutics
  • JW Pharmaceutical
  • BiologicsMD

For more information, visit Alopecia Market Analysis, Patient Pool, and Emerging Therapies

Scope of the Alopecia Market Report:

  • 11 Years Forecast
  • 7MM Coverage 
  • Descriptive overview of Alopecia, causes, signs and symptoms, diagnosis, treatment
  • Comprehensive insight into Alopecia epidemiology in the 7MM
  • Alopecia marketed and emerging therapies 
  • Alopecia companies
  • Alopecia market drivers and barriers 

Key Questions Answered in the Alopecia Market Report 2032:

  • What was the Alopecia market share distribution in 2019, and how would it appear in 2032?
  • What is the total Alopecia market size and the market size by therapy across the 7MM for the study period (2019-32)?
  • What are the important findings from 7MM, and which country will have the greatest Alopecia market size from 2019-32?
  • During the study period (2019-2032), at what CAGR is the Alopecia market projected to expand at 7MM?

Table of Contents:

1 Alopecia Market Key Comprehensive Insights 

2 Alopecia Market Report Introduction

3 Competitive Intelligence Analysis for Alopecia

4 Alopecia Market Analysis Overview at a Glance

5 Executive Summary of Alopecia

6 Alopecia Epidemiology and Market Methodology

7 Alopecia Epidemiology and Patient Population

8 Alopecia Patient Journey

9 Alopecia Treatment Algorithm, Alopecia Current Treatment, and Medical Practices

10 Key Endpoints in Alopecia Clinical Trials

11 Alopecia Marketed Therapies 

12 Alopecia Emerging Therapies

13 Alopecia: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Alopecia

16 Alopecia Market Key Opinion Leaders Reviews

18 Alopecia Market Drivers

19 Alopecia Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Alopecia Epidemiology 2032

DelveInsight's "Alopecia - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Alopecia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Alopecia Pipeline 2023

"Alopecia Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Alopecia market. A detailed picture of the Alopecia pipeline landscape is provided, which includes the disease overview and Alopecia treatment guidelines. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.